These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32259790)

  • 1. Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials.
    Hazim A; Mills G; Prasad V; Haslam A; Chen EY
    J Natl Compr Canc Netw; 2020 Apr; 18(4):428-433. PubMed ID: 32259790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium.
    Bautista F; Moreno L; Marshall L; Pearson ADJ; Geoerger B; Paoletti X
    Eur J Cancer; 2017 Nov; 86():275-284. PubMed ID: 29055843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.
    Penel N; Duhamel A; Adenis A; Devos P; Isambert N; Clisant S; Bonneterre J
    Invest New Drugs; 2012 Apr; 30(2):653-61. PubMed ID: 21049280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.
    Nikanjam M; Liu S; Kurzrock R
    Int J Cancer; 2016 Nov; 139(9):2135-41. PubMed ID: 27389805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse.
    Jain RK; Lee JJ; Hong D; Markman M; Gong J; Naing A; Wheler J; Kurzrock R
    Clin Cancer Res; 2010 Feb; 16(4):1289-97. PubMed ID: 20145187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials.
    Hirakawa A; Yonemori K; Kinoshita F; Kobayashi Y; Okuma HS; Kawachi A; Tamura K; Fujiwara Y; Rubinstein L; Harris PJ; Takebe N
    Cancer Sci; 2018 Jan; 109(1):207-214. PubMed ID: 29114963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
    Simmet V; Eberst L; Marabelle A; Cassier PA
    Ann Oncol; 2019 Nov; 30(11):1751-1759. PubMed ID: 31435659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
    Infante JR; Camidge DR; Mileshkin LR; Chen EX; Hicks RJ; Rischin D; Fingert H; Pierce KJ; Xu H; Roberts WG; Shreeve SM; Burris HA; Siu LL
    J Clin Oncol; 2012 May; 30(13):1527-33. PubMed ID: 22454420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs.
    Mittapalli RK; Yin D; Beaupre D; Palaparthy R
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):23-30. PubMed ID: 33237334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
    Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
    Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
    Chiuzan C; Shtaynberger J; Manji GA; Duong JK; Schwartz GK; Ivanova A; Lee SM
    J Biopharm Stat; 2017; 27(3):477-494. PubMed ID: 28166468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.
    van Brummelen EM; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):235-42. PubMed ID: 26960536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.
    Altzerinakou MA; Collette L; Paoletti X
    J Natl Cancer Inst; 2019 Nov; 111(11):1179-1185. PubMed ID: 30838405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pediatric phase I trials in oncology: an analysis of study conduct efficiency.
    Lee DP; Skolnik JM; Adamson PC
    J Clin Oncol; 2005 Nov; 23(33):8431-41. PubMed ID: 16293874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan.
    Shimomura A; Kondo S; Kobayashi N; Iwasa S; Kitano S; Tamura K; Fujiwara Y; Yamamoto N
    Int J Clin Oncol; 2017 Aug; 22(4):780-785. PubMed ID: 28293794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials.
    Gupta S; Hunsberger S; Boerner SA; Rubinstein L; Royds R; Ivy P; LoRusso P
    J Natl Cancer Inst; 2012 Dec; 104(24):1860-6. PubMed ID: 23169991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults' trials.
    Paoletti X; Geoerger B; Doz F; Baruchel A; Lokiec F; Le Tourneau C
    Eur J Cancer; 2013 Jul; 49(10):2392-402. PubMed ID: 23540589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs.
    Jardim DL; Hess KR; Lorusso P; Kurzrock R; Hong DS
    Clin Cancer Res; 2014 Jan; 20(2):281-8. PubMed ID: 24190980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.